Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Isabell Brikell

Showing results (31-40 of 104) with videos related to

Pageof 11
Sort By:
Translational Psychiatry|April 11, 2022
The role of ADHD genetic risk in mid-to-late life somatic health conditionsMiguel Garcia-Argibay, Ebba du Rietz, Yi Lu, et al.
Epilepsia|January 26, 2019
Medication treatment for attention-deficit/hyperactivity disorder and the risk of acute seizures in individuals with epilepsyIsabell Brikell, Qi Chen, Ralf Kuja-Halkola, et al.
World Psychiatry : Official Journal of the World Psychiatric Association (WPA)|September 8, 2022
Attention-deficit/hyperactivity disorder as a risk factor for cardiovascular diseases: a nationwide population-based cohort studyLin Li, Zheng Chang, Jiangwei Sun, et al.
Plos Medicine|October 18, 2024
Risk of common psychiatric disorders, suicidal behaviours, and premature mortality following violent victimisation: A matched cohort and sibling-comparison study of 127,628 people who experienced violence in Finland and SwedenAmir Sariaslan, Joonas Pitkänen, Jonas Forsman, et al.
JAMA Psychiatry|June 25, 2025
Increased Prescribing of Attention-Deficit/Hyperactivity Disorder Medication and Real-World Outcomes Over TimeLin Li, David Coghill, Arvid Sjölander, et al.
Journal of the American Academy of Child and Adolescent Psychiatry|January 25, 2026
Second-Generation Antipsychotics and Real-World Outcomes in Youth With On- and Off-Label IndicationsLe Zhang, Patrick D Quinn, Johan Bjureberg, et al.
BMJ Mental Health|June 25, 2026
Risk of subsequent self-harm, suicide attempts and suicide following a first hospital-treated self-harm episode among young people: a population-based cohort studyThuy-Dung Nguyen, Moa Karemyr, Ralf Kuja-Halkola, et al.
JAMA Psychiatry|September 27, 2023
Antidepressant Use and Risk of Manic Episodes in Children and Adolescents With Unipolar DepressionSuvi Virtanen, Tyra Lagerberg, Christine Takami Lageborn, et al.
Journal of Psychopharmacology (Oxford, England)|February 16, 2026
Central nervous system acting medication used by young adults with borderline personality disorder in Sweden 2006-2019Annika Tiger, Yasmina Molero, Isabell Brikell, et al.
The Lancet. Psychiatry|January 9, 2025
Evaluating ADHD medication trial representativeness: a Swedish population-based study comparing hypothetically trial-eligible and trial-ineligible individualsMiguel Garcia-Argibay, Zheng Chang, Isabell Brikell, et al.
Pageof 11

Showing results (31-40 of 104) with videos related to

Sort By:
Pageof 11
Translational Psychiatry|April 11, 2022
The role of ADHD genetic risk in mid-to-late life somatic health conditionsMiguel Garcia-Argibay, Ebba du Rietz, Yi Lu, et al.
Epilepsia|January 26, 2019
Medication treatment for attention-deficit/hyperactivity disorder and the risk of acute seizures in individuals with epilepsyIsabell Brikell, Qi Chen, Ralf Kuja-Halkola, et al.
World Psychiatry : Official Journal of the World Psychiatric Association (WPA)|September 8, 2022
Attention-deficit/hyperactivity disorder as a risk factor for cardiovascular diseases: a nationwide population-based cohort studyLin Li, Zheng Chang, Jiangwei Sun, et al.
Plos Medicine|October 18, 2024
Risk of common psychiatric disorders, suicidal behaviours, and premature mortality following violent victimisation: A matched cohort and sibling-comparison study of 127,628 people who experienced violence in Finland and SwedenAmir Sariaslan, Joonas Pitkänen, Jonas Forsman, et al.
JAMA Psychiatry|June 25, 2025
Increased Prescribing of Attention-Deficit/Hyperactivity Disorder Medication and Real-World Outcomes Over TimeLin Li, David Coghill, Arvid Sjölander, et al.
Journal of the American Academy of Child and Adolescent Psychiatry|January 25, 2026
Second-Generation Antipsychotics and Real-World Outcomes in Youth With On- and Off-Label IndicationsLe Zhang, Patrick D Quinn, Johan Bjureberg, et al.
BMJ Mental Health|June 25, 2026
Risk of subsequent self-harm, suicide attempts and suicide following a first hospital-treated self-harm episode among young people: a population-based cohort studyThuy-Dung Nguyen, Moa Karemyr, Ralf Kuja-Halkola, et al.
JAMA Psychiatry|September 27, 2023
Antidepressant Use and Risk of Manic Episodes in Children and Adolescents With Unipolar DepressionSuvi Virtanen, Tyra Lagerberg, Christine Takami Lageborn, et al.
Journal of Psychopharmacology (Oxford, England)|February 16, 2026
Central nervous system acting medication used by young adults with borderline personality disorder in Sweden 2006-2019Annika Tiger, Yasmina Molero, Isabell Brikell, et al.
The Lancet. Psychiatry|January 9, 2025
Evaluating ADHD medication trial representativeness: a Swedish population-based study comparing hypothetically trial-eligible and trial-ineligible individualsMiguel Garcia-Argibay, Zheng Chang, Isabell Brikell, et al.
Pageof 11